The Farnesyltransferase Inhibitor R115777 Reduces Hypoxia and Matrix Metalloproteinase 2 Expression in Human Glioma Xenograft

Clinical Cancer Research

Volumn 9, Issue 16 I, 2003, Pages 6062-6068

  Delmas, Caroline ^a   End, Dave ^b   Rochaix, Philippe ^a   Favre, Gilles ^a   Toulas, Christine ^a   Cohen Jonathan, Elizabeth ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b Analytical Chemistry Drug Evaluation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITROIMIDAZOLE; CELL MARKER; GELATINASE A; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TIPIFARNIB;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; BRAIN TUMOR; CANCER GRADING; CELL HYPOXIA; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; FLUORINATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INHIBITION KINETICS; NEOVASCULARIZATION (PATHOLOGY); OXYGENATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION; TUMOR VOLUME; WILD TYPE; XENOGRAFT;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; QUINOLONES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0347364771     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Nozue, M., Lee, I., Yuan, F., Teicher, B. A., Brizel, D. M., Dewhirst, M. W., Milross, C. G., Milas, L., Song, C. W., Thomas, C. D., Guichard, M., Evans, S. M., Koch, C. J., Lord, E. M., Jain, R. K., and Suit, H. D. Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker. J. Surg. Oncol., 66: 30-38, 1997.
2. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., and Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys., 38: 285-289, 1997.
3. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., and Dewhirst, M. W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res., 56: 941-943, 1996.
4. Hockel, M., Knoop, C., Schlenger, K., Vorndran, B., Knapstein, P. G., and Vaupel, P. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv. Exp. Med. Biol., 345: 445-450, 1994.
5. Uhm, J. H., Dooley, N. P., Villemure, J. G., and Yong, V. W. Glioma invasion in vitro: regulation by matrix metalloprotease-2 and protein kinase C. Clin. Exp. Metastasis, 14: 421-433, 1996.
6. Barrington, R. E., Subler, M. A., Rands, E., Omer, C. A., Miller, P. J., Hundley, J. E., Koester, S. K., Troyer, D. A., Bearss, D. J., Conner, M. W., Gibbs, J. B., Hamilton, K., Koblan, K. S., Mosser, S. D., O'Neill, T. J., Schaber, M. D., Senderak, E. T., Windle, J. J., Oliff, A., and Kohl, N. E. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell Biol., 18: 85-92, 1998.
7. Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., and Lee, T. J. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA, 91: 9141-9145, 1994.
8. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res., 55: 4243-4247, 1995.
9. End, D. W., Smets, G., Todd, A. V., Applegate, T. L., Fuery, C. J., Angibaud, P., Venet, M., Sanz, G., Poignet, H., Skrzat, S., Devine, A., Wouters, W., and Bowden, C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res., 61: 131-137, 2001.
10. 2 delay in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and v-myc. Radiat. Res., 125: 283-287, 1991.
11. McKenna, W. G., Weiss, M. C., Bakanauskas, V. J., Sandler, H., Kelsten, M. L., Biaglow, J., Tuttle, S. W., Endlich, B., Ling, C. C., and Muschel, R. J. The role of the H-ras oncogene in radiation resistance and metastasis. Int. J. Radiat. Oncol. Biol. Phys., 18: 849-859, 1990.
12. Cohen-Jonathan, E., Muschel, R. J., Gillies, M. W., Evans, S. M., Cerniglia, G., Mick, R., Kusewitt, D., Sebti, S. M., Hamilton, A. D., Oliff, A., Kohl, N., Gibbs, J. B., and Bernhard, E. J. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat. Res., 154: 125-132, 2000.
13. Bernhard, E. J., Kao, G., Cox, A. D., Sebti, S. M., Hamilton, A. D., Muschel, R. J., and McKenna, W. G. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res., 56: 1727-1730, 1996.
14. Bernhard, E. J., McKenna, W. G., Hamilton, A. D., Sebti, S. M., Qian, Y., Wu, J. M., and Muschel, R. J. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res., 58: 1754-1761, 1998.
15. Cohen-Jonathan, E., Evans, S. M., Koch, C. J., Muschel, R. J., McKenna, W. G., Wu, J., and Bernhard, E. J. The farnesyltransferase inhibitor L744, 832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res., 61: 2289-2293, 2001.
16. Cohen-Jonathan, E., Toulas, C., Ader, I., Monteil, S., Allal, C., Bonnet, J., Hamilton, A. D., Sebti, S. M., Daly-Schveitzer, N., and Favre, G. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS. Radiat. Res., 152: 404-411, 1999.
17. Delmas, C., Heliez, C., Cohen-Jonathan, E., End, D., Bonnet, J., Favre, G., and Toulas, C. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int. J. Cancer, 100: 43-48, 2002.
18. Ader, I., Toulas, C., Dalenc, F., Delmas, C., Bonnet, J., Cohen-Jonathan, E., and Favre, G. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene, 21: 5998-6006, 2002.
19. Dalenc, F., Drouet, J., Ader, I., Delmas, C., Rochaix, P., Favre, G., Cohen-Jonathan, E., and Toulas, C. Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells. Int. J. Cancer, 100: 662-668, 2002.
20. Deb, S., Zhang, J. W., and Gottschall, P. E. Activated isoforms of MMP-2 are induced in U87 human glioma cells in response to β-amyloid peptide. J. Neurosci. Res., 55: 44-53, 1999.
21. Bello, L., Lucini, V., Carrabba, G., Giussani, C., Machluf, M., Pluderi, M., Nikas, D., Zhang, J., Tomei, G., Villani, R. M., Carroll, R. S., Bikfalvi, A., and Black, P. M. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res., 61: 8730-8736, 2001.
22. Gingras, D., Page, M., Annabi, B., and Beliveau, R. Rapid activation of matrix metalloproteinase-2 by glioma cells occurs through a posttranslational MT1-MMP-dependent mechanism. Biochim. Biophys. Acta, 1497: 341-350, 2000.
23. Bernsen, H. J., Rijken, P. F., Peters, H., Bakker, H., and van der Kogel, A. J. The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J. Neurooncol., 38: 51-57, 1998.
24. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
25. Bernsen, H. J., Rijken, P. F., Peters, J. P., Bakker, J. H., Boerman, R. H., Wesseling, P., and van der Kogel, A. J. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J. Neurooncol., 44: 129-136, 1999.
26. Gu, W. Z., Tahir, S. K., Wang, Y. C., Zhang, H. C., Cherian, S. P., O'Connor, S., Leal, J. A., Rosenberg, S. H., and Ng, S. C. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur. J. Cancer, 35: 1394-1401, 1999.
27. Kurimoto, M., Hirashima, Y., Hamada, H., Kamiyama, H., Nagai, S., Hayashi, N., and Endo, S. In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620. J. Neurooncol., 61: 103-112, 2003.
28. Feldkamp, M. M., Lau, N., and Guha, A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene, 18: 7514-7526, 1999.
29. Wang, I. K., Lin-Shiau, S. Y., and Lin, J. K. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology, 59: 245-254, 2000.
30. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood, 90: 3322-3331, 1997.